Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00155246
Status:
COMPLETED
Last Update Posted:
2010-01-29
First Post:
2005-09-08
Brief Title:
Efficacy of Pentoxifylline on Chronic Kidney Disease
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study whether pentoxifylline has additive renoprotective effect in patients taking ARB
Detailed Description:
In patients with CKD and serum creatinine 1360 mdgl having taken losartan 100 mgday for at least 3 months with stable renal function will be recruited to a randomized open-label trial Patients taking pentoxifylline or not will be compared for their spot urinary proteinuria estimated glomerular filtration spot urine tumor necrosis factor-αcreatinine ratio spot urine monocyte-chemoattractant protein-1creatinine and aldosterone concentration between groups in a 2-year study Add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None